



Disclaimer

Earnings forecasts are produced by the contributing registered investment analysts currently covering RB.

The estimates that are used to compile the consensus are the sole responsibility of the registered investment analysts. RB uses Vuma to compile the consensus information, and does not endorse or concur with such analyst information, conclusions or recommendations. RB has not verified any of the information received and none of RB, its affiliates or any of its or their respective directors, officers and employees make any representation or warranty, express or implied, as to, or accepts any responsibility for, the accuracy or completeness of the consensus information. RB shall not be liable (whether in contract, tort or otherwise) for any errors, inaccuracies or omissions in the content of the information (either at the date of issue of these forecasts, or any other date), or for any action taken in reliance thereon. RB does not assume any responsibility to update, revise or supplement such information.

The information provided by RB is for information purposes only and is not intended for trading purposes. It should be noted that forecasts are forward-looking and are therefore subject to risks and uncertainties (including unknown risks and uncertainties) that may materially affect eventual results.

THE FORECASTS PROVIDED ARE BASED ON A MEAN AVERAGE OF ESTIMATES PROVIDED AND DO NOT REPRESENT OR REFLECT, AND SHOULD NOT BE DEEMED TO BE, RB'S OPINIONS, ESTIMATES OR FORECASTS.



	Q2 FY20 CONSENSUS 20/07/20	Q2 FY20 MIN	Q2 FY20 MAX	H1 FY20 CONSENSUS 20/07/20	H1 FY20 MIN	H1 FY20 MAX	FY20 CONSENSUS 20/07/20	FY20 MIN	FY20 MAX	FY21 CONSENSUS 20/07/20	FY21 MIN	FY21 MAX	FY22 CONSENSUS 20/07/20	FY22 MIN	FY22 MAX
Reckitt Benckiser Group Plc															
<i>Net Revenue Growth: Like for Like %</i>															
IFCN	-4.7	-9.0	3.4	-3.1	-5.3	0.9	-0.6	-2.5	1.5	2.4	-3.0	4.5	3.4	2.0	4.5
OTC	-5.1	-15.1	5.0	15.6	10.7	20.0	8.4	1.4	13.1	0.6	-7.0	5.0	4.1	3.0	6.0
Other	19.9	10.0	27.0	18.7	13.5	22.2	12.9	7.1	18.6	0.9	-4.0	4.0	4.5	2.0	6.5
Rest of Health	10.3	-1.6	15.2	17.4	15.3	19.3	10.7	6.6	12.6	1.0	-4.8	3.8	4.5	2.8	6.3
Total Health	4.6	-2.2	9.2	9.4	7.9	11.4	6.6	5.2	8.2	1.4	-2.6	3.9	4.0	2.5	5.7
Hygiene Home	12.9	6.0	20.6	13.0	10.4	16.6	9.1	6.4	13.5	1.9	-1.6	8.0	4.0	2.5	7.0
Group growth: like-for-like %	7.8	0.8	10.6	10.6	7.2	11.9	7.5	5.1	9.7	1.4	-1.9	3.9	3.9	2.7	5.0
<i>Net M&A impact %</i>	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.2	<i>n/a</i>	<i>n/a</i>	<i>n/a</i>	0.0	0.0	0.0
<i>FX impact %</i>	-2.0	-6.0	1.4	-1.5	-3.5	0.3	-1.7	-3.5	0.9	0.0	-0.9	0.6	-0.6	-0.9	0.0
Group growth: Net Revenue growth (Actual rates) - continuing operations %	5.8	1.9	8.6	9.2	7.1	10.3	5.9	3.7	7.5	1.4	-1.9	3.9	3.7	1.8	5.0
Net Revenue - Total Reported £															
IFCN	710	650	780	1,456	1,396	1,526	2,918	2,771	3,010	2,987	2,736	3,130	3,088	2,791	3,304
OTC	390	341	524	1,005	959	1,101	2,082	1,939	2,201	2,091	1,937	2,205	2,175	2,014	2,337
Other	864	786	922	1,692	1,612	1,747	3,201	2,989	3,330	3,226	2,948	3,405	3,363	3,096	3,610
Rest of Health	1,246	1,150	1,310	2,690	2,593	2,753	5,279	5,190	5,402	5,333	4,885	5,594	5,559	5,110	5,947
Total Health	1,956	1,892	2,045	4,145	4,081	4,234	8,197	8,040	8,401	8,309	7,792	8,725	8,632	8,110	9,218
Hygiene Home	1,307	1,227	1,390	2,662	2,582	2,745	5,390	5,190	5,691	5,472	5,255	5,662	5,659	5,387	5,888
Total Net Revenue	3,263	3,141	3,353	6,807	6,683	6,895	13,587	13,316	13,799	13,781	13,059	14,339	14,291	13,496	15,057
Operating Profit - Adjusted															
Health				954	832	1,040	1,901	1,747	2,071	1,925	1,793	2,047	2,074	1,873	2,228
Hygiene Home				584	516	646	1,295	1,187	1,407	1,310	1,164	1,411	1,388	1,242	1,526
Total Operating Profit - Adjusted				1,538	1,348	1,642	3,195	3,022	3,300	3,236	3,069	3,436	3,462	3,158	3,686
Operating Margin % - Adjusted															
Health				23.0	20.2	25.0	23.2	21.2	25.0	23.2	21.2	25.0	24.0	23.0	25.7
Hygiene Home				21.9	19.9	23.5	24.0	22.8	25.6	23.9	22.0	25.1	24.5	22.8	25.9
Total Operating Margin % - Adjusted				22.6	20.1	23.9	23.5	22.7	24.4	23.5	22.6	24.6	24.2	23.4	25.2
Net Finance Expense - Adjusted															
Taxation (expense)/benefit - Adjusted				-157	-203	-123	-304	-323	-245	-279	-316	-222	-250	-288	-196
Non-controlling Interest				-318	-337	-274	-660	-683	-621	-676	-730	-637	-735	-798	-673
				-9	-12	-6	-14	-25	-10	-14	-25	-8	-15	-26	-8
Continuing Operations															
Net income - adjusted				1,099	917	1,462	2,226	2,071	2,315	2,277	2,118	2,427	2,463	2,186	2,654
Average number of shares on a diluted basis				710.0	708.7	715.0	710.5	708.7	717.7	712.0	708.7	723.2	713.5	708.7	728.7
EPS, Group, fully diluted, adjusted (p)				154.8	129.3	206.3	313.4	292.1	326.5	319.9	296.6	342.4	345.3	300.7	374.5